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Drug induced genes The transcriptional response to six commonly- abused drugs was assessed in the mouse brain  revealing common modules of drug-induced  genes.
Abstract
Background: Various drugs of abuse activate intracellular pathways in the brain reward system. These pathways 
regulate the expression of genes that are essential to the development of addiction. To reveal genes common and 
distinct for different classes of drugs of abuse, we compared the effects of nicotine, ethanol, cocaine, morphine, heroin 
and methamphetamine on gene expression profiles in the mouse striatum.
Results: We applied whole-genome microarray profiling to evaluate detailed time-courses (1, 2, 4 and 8 hours) of 
transcriptome alterations following acute drug administration in mice. We identified 42 drug-responsive genes that 
were segregated into two main transcriptional modules. The first module consisted of activity-dependent transcripts 
(including Fos and Npas4), which are induced by psychostimulants and opioids. The second group of genes (including 
Fkbp5 and S3-12), which are controlled, in part, by the release of steroid hormones, was strongly activated by ethanol 
and opioids. Using pharmacological tools, we were able to inhibit the induction of particular modules of drug-related 
genomic profiles. We selected a subset of genes for validation by in situ hybridization and quantitative PCR. We also 
showed that knockdown of the drug-responsive genes Sgk1 and Tsc22d3 resulted in alterations to dendritic spines in 
mice, possibly reflecting an altered potential for plastic changes.
Conclusions: Our study identified modules of drug-induced genes that share functional relationships. These genes 
may play a critical role in the early stages of addiction.
Background
Drug addiction is a brain disease with prominent hazard-
ous effects, including the collapse of health and social and
economic status [1]. Acute exposure to drugs of abuse
initiates molecular and cellular alterations in the central
nervous system [2,3] that lead to an increased overall vul-
nerability to addiction with subsequent drug exposures
[4]. These drug-induced alterations employ changes in
gene transcription that result in the synthesis of new pro-
teins [5]. Therefore, one of the important goals of addic-
tion research is to identify the drug-induced gene
expression changes in the specific brain structures that
are related to the addictive properties of various drugs.
The major neural target sites of addictive drugs are the
ventral and the dorsal striatum, that is, the brain regions
that control reward sensitivity, motor function and habit
learning [6]. The dorsal striatum is thought to underlie
stimulus-response and spatial learning, and the ventral
striatum is involved in appetitive behavior and reinforce-
ment [7,8]. However, to some extent, these functions
might overlap [9,10]. All addictive drugs elevate dop-
amine levels in the striatum, and this effect is associated
with reinforcing drug properties [11]. However, the phar-
macological mechanisms and neural substrates involved
in mediating the rewarding action are different for vari-
ous drugs. Psychostimulants directly influence extracellu-
lar dopamine levels in the striatum through inhibitory
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effects on dopamine reuptake [12,13]. Opiates inhibit
GABAergic inhibitory neurons in the ventral tegmental
area and activate dopaminergic neurons projecting to the
striatum [14]. In addition, opiates directly bind to opioid
receptors located on striatal interneurons [15]. Ethanol
acts on GABAergic interneurons in the ventral tegmental
area that, in turn, modulate the activity of dopaminergic
neurons and the action of neurotransmitter-gated ion
channels [16]. Nicotine enhances reward-related dop-
amine release by activating nicotinic acetylcholine recep-
tors [17,18]. Therefore, it is believed that the combination
of dopamine-dependent neurotransmission and endoge-
nous opioid-dependent modulation is responsible for the
acquisition of drug addiction [4,19]. The molecular and
genomic mechanisms by which drugs of abuse induce
neuroplastic changes related to addiction remain largely
unknown [20].
Several studies have evaluated changes in gene expres-
sion profiles in the brain after administration of drugs of
abuse (reviewed in [21]). Exposure to psychostimulants
induces the activity-dependent gene expression of several
transcription activators and repressors [22,23]. Opioids
and ethanol regulate the transcription of genes involved
in metabolic functions and a group of genes encoding
heat-shock proteins [24-28].
Genomic research strategies have recently transitioned
from the search for unknown genes to the identification
and evaluation of coordinated gene networks and tran-
scriptional signatures [29]. New opportunities arising
from the analysis of these networks include identifying
novel relationships between genes and signaling path-
ways, connecting biological processes with the regulation
of gene transcription, and associating genes and gene
expression with diseases [30,31]. The identification of
gene networks requires large gene expression data sets
with multiple data points [32]. The transcriptional
response to a drug treatment analyzed during a time-
course suits the above strategy perfectly.
Exploring dynamic changes in brain gene expression
profiles is possible only in animal models. In these mod-
els, assessments of the behavioral effects of drugs of
abuse are well established. Therefore, integrating brain
gene transcription and phenotypic information provides
us with a unique opportunity to associate the addictive
potential of the drugs with the molecular responses acti-
vated by these drugs [33,34]. The limitations of such a
strategy include differences in drug responses between
humans and rodents and the extreme complexity of the
analyzed tissue. Despite these limitations, the obtained
results may provide new insights into the molecular con-
trol of drug addiction.
In this study, we aimed to identify the transcriptional
networks activated by different classes of addictive drugs
and to translate the gene expression patterns into biologi-
cal themes that are related to the development of addic-
tion.
Results
Comparison of rewarding and stimulant drug properties
In the present study, we assessed the behavioral and tran-
scriptional effects of cocaine (25 mg/kg intraperitoneally
(i.p.)), methamphetamine (2 mg/kg i.p.), morphine (20
mg/kg i.p.), heroin (10 mg/kg i.p.), ethanol (2 g/kg i.p.)
and nicotine (1 mg/kg i.p.) on C57BL/6J mice. Drug doses
previously reported to generate rewarding and addictive
responses in mice were selected [35-37]. The rewarding
properties were compared in our laboratory. Conditioned
place preference (CPP) tests were performed using an
unbiased procedure in a three-arm apparatus. Cocaine,
morphine, heroin and methamphetamine treatment
induced a robust preference for the drug-paired compart-
ment (ANOVA, Newman-Keuls test, P < 0.05; Figure 1a).
For ethanol and nicotine, the procedure was increased to
five sessions of conditioning. Ethanol treatment induced
a moderate effect in the CPP test (t-test, P < 0.05). Nico-
tine treatment produced a tendency for place preference,
which may be associated with a very narrow effective
dose range for reinforcing the effects of nicotine in mice.
An independent group of animals was tested for drug-
induced motor behavior. Cocaine, methamphetamine,
heroin and morphine treatment significantly increased
locomotor activity following acute drug administration
(repeated-measures ANOVA, Newman-Keuls test, P  <
0.05; Figure 1b). Ethanol and nicotine treatment did not
produce locomotor activation in comparison to saline-
treated controls. The behavioral data were further used to
analyze associations between phenotypes and transcrip-
tome alterations.
Whole-genome gene expression profiling
We applied a strategy of detailed time-course studies of
gene expression alterations following acute administra-
tion of various drugs of abuse using Illumina Whole-
Genome 6 microarrays. To analyze the dynamics of early,
intermediate and relatively late changes in mRNA abun-
dance, the analysis was performed at four time points (1,
2, 4 and 8 h following drug injection).
Microarray data analysis using two-way ANOVA iden-
tified 42 drug-responsive genes with P < 1 × 10-6 (corre-
sponding to P < 0.05 after adjusting for approximately
48,000 independent tests using Bonferroni correction;
Figure 2). Compared to other gene expression profiling
studies, the statistical threshold was rather conservative.
However, the same threshold is widely accepted in popu-
lation genetic and genome-wide association studies in
humans [38]. The difference between the methodological
standards may result from the number of samples and
biological replicates usually used in these two types ofPiechota et al. Genome Biology 2010, 11:R48
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whole-genome studies. The present study contained (rel-
atively) many high-quality samples, allowing it to satisfy
restrictive statistical criteria.
Furthermore, we estimated the false discovery rate
(percent FDR) to answer the question of how large was
the fraction of drug-responsive genes discovered at the
assumed threshold [39]. The maximum number of true
positive genes altered in the striatum by drugs of abuse
(drug factor, 104 transcripts) was found at a 29% FDR.
Beyond that level, the number of true positives did not
increase. Surprisingly, the number of true positives
remained stable (84 to 104 transcripts, mean = 94.4 ± 4.9)
over a wide range of FDR (4.7 to 56.3%). The results for
the drug factor are in contrast to alterations in the striatal
gene expression profile related to the time point of the
experiment (time factor). The maximum number of true
positive genes (5,442 transcripts) for the time factor was
Figure 1 Comparison of the reinforcing and activating effects of drugs of abuse in C57BL/6J mice. (a) Bar graph summarizing the development 
of CPP to morphine, heroin, ethanol, nicotine, methamphetamine, cocaine or saline injections (i.p.). The number of drug conditioning sessions is in-
dicated in parentheses. The level of significance was measured using ANOVA following the Newman-Keuls post-hoc test for drug versus saline; *P < 
0.05; **P < 0.01 (n = 6 to 12). (b) Graph summarizing locomotor activation in response to drug treatment measured as increased ambulation in an 
activity cage during 4 h (n = 5). (c,d) Analysis of correlations between drug-induced changes in gene expression and behavioral effects of drugs in 
mice (Additional file 9). Scatter plots present the most significant correlation between the behavioral effects (y-axis) and the level of drug-induced 
transcription (x-axis). Correlation with locomotor activation was computed using data for each particular time point.
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found at a 69.8% FDR and increased linearly in the range
0.1 to 69.8% FDR (Additional file 1).
The above observations suggest a rather unexpected
conclusion. While the diurnal cycle alters a vast fraction
of the brain transcriptome, drugs regulated the expres-
sion of a limited number of genes (approximately 100),
and this alteration was robust. The number of genes
obtained using Bonferroni correction (42 transcripts) was
equal to the number of genes obtained at a 0.1% FDR
threshold. Therefore, at the chosen threshold, we identi-
fied 40.3% (42 of 104 transcripts) of genes altered by
drugs of abuse with 99.9% confidence. The complete
results of the ANOVA, including two different methods
of correction for multiple comparisons (Bonferroni cor-
rection and percent FDR) for both time and drug factors
are provided in Additional file 2.
The changes in mRNA abundance of selected marker
genes were validated by quantitative PCR (qPCR) using
aliquots of the non-pooled total RNA (Figure 3a; Addi-
tional file 3), yielding an overall correlation between the
microarray and qPCR results of r = 0.69 (Spearman's
method, P = 4.87 × 10-24). The alterations in mRNA level
were also confirmed in an independent experiment. In
addition, the expression of the selected genes was evalu-
ated during the acquisition and expression of morphine-
induced CPP (Figure 3b).
Identification of drug-regulated gene expression patterns
Hierarchical clustering revealed two major drug-respon-
sive gene transcription patterns (arbitrarily described as
A and B; Figure 2a). Pattern B consisted of three subse-
quent subclusters (arbitrarily described as B1, B2 and B3).
Example genes from the particular patterns include: pat-
tern A, Fos, Egr2 and Homer1; pattern B1, Sgk1, Plekhf1
and  Rasd1; pattern B2,  Tsc22d3,  Cdkn1a  and  Map3k6;
and pattern B3, Fkbp5, S3-12 and Sult1a1.
To search for other drug-responsive transcriptional
networks, we performed additional hierarchical cluster-
ing on the lists of genes obtained with 5% (a threshold
commonly used in the literature) and 29% (the maximum
number of true positive results) FDRs. With these less
restrictive statistical criteria, we found no other networks
with distinct gene expression profiles (Additional file 4).
Assuming that we identified all the major gene patterns
altered by drugs of abuse and taking into consideration
Figure 2 Hierarchical clustering of drug-dependent transcriptional alterations in mouse striatum. (a) Microarray results are shown as a heat 
map and include genes with a genome-wide significance from two-way ANOVA of the drug factor. Colored rectangles represent transcript abun-
dance (Additional file 2) 1, 2, 4 and 8 h after injection of the drug indicated above of the gene labeled on the right. The intensity of the color is pro-
portional to the standardized values (between -2 and 2) from each microarray, as indicated on the bar below the heat map image. Clustering was 
performed using Euclidean distance according to the scale on the left. Major drug-responsive gene transcription patterns are arbitrarily described as 
'A', 'B1', 'B2' and 'B3. (b) Gene cluster analysis using data-mining methods (Table 1). The fold cellular enrichment (2, 5 or 20 in a particular cell popula-
tion, as reported in Cahoy et al. [101]) of the selected transcripts in various cell types is indicated by N (neurons), A (astrocytes) or O (oligodendrocytes). 
Over-representation of transcription factor binding site (TFBSs), as indicated on the left, was identified using the cREMaG database (see Materials and 
methods). The statistical significance of enrichment is marked as *P < 0.05.
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the fact that Bonferroni correction for multiple testing is
very conservative, lists of genes with a significant level of
Pearson's correlation to the main clusters (P < 1 × 10-10;
FDR for this analysis was estimated at <0.1%) were
extracted and analyzed.
Gene Ontology (GO) enrichment, literature mining
and identification of cis-regulatory elements was per-
formed on extended lists of transcripts from each gene
expression pattern: A, 38 genes; B1, 45 genes; B2, 31
genes; and B3, 18 genes. Due to the similar profiles of the
B1 and B2, as well as the B2 and B3, gene subsets, the lists
partially overlapped by 27% and 45%, respectively (Addi-
tional file 2). One gene (Car12) was excluded from the
analysis due to its outlying gene expression profile.
The drug-responsive genes are randomly distributed
throughout the entire mouse genome. Chromosome
localizations are shown in Additional file 5.
Comparison of drug effects on the striatal transcriptome
The results of gene expression profiling revealed differ-
ences and similarities in the transcriptional responses to
the various drugs (Figure 2; Additional file 6). Pattern A
was induced 1 to 2 h after injection of cocaine or meth-
amphetamine and 4 h after injection of morphine or her-
oin. Pattern B consisted of three subsequent subclusters:
B1, induced 1 to 2 h after injection of ethanol, morphine,
heroin, methamphetamine and cocaine; B2, induced 2 to
4 h after injection of ethanol, morphine, heroin and
methamphetamine; and B3, induced 4 h after injection of
ethanol, morphine and heroin. The only pattern common
to all inspected drugs was pattern B1. However, this pat-
tern was induced by different drugs to different degrees.
The drugs were divided into two groups. One, includ-
ing cocaine and methamphetamine, exhibited high and
early induction of pattern A and low or absent induction
of pattern B. The second group, including ethanol, mor-
phine and heroin, elicited high induction of pattern B.
The complete results of a Tukey's post-hoc test (P < 0.05,
drug versus saline) after ANOVA are provided in Addi-
tional file 2.
Functional classification of drug-responsive genes
To identify functional associations between the genes
with expression induced by drugs, we used three different
data-mining tools (Figure 2b, Table 1). To characterize
the transcriptional representation of biological processes,
a list of genes from each gene expression pattern was ana-
lyzed by GO. Among the most abundant group of genes
in pattern A, functional clusters of transcripts connected
with protein phosphatase activity (32.4-fold enrichment,
P < 0.01; for example, Dusp1, Dusp6), rhythmic processes
(14.7-fold, P < 0.05; for example, Per1, Per2) and tran-
scriptional regulatory activity (3-fold, P  < 0.001; for
example, Fos, Egr2) were over-represented.
The group of genes from pattern B1 was enriched in
transcripts involved in small GTPase-mediated signal
transduction (5.9-fold, P  < 0.01; for example, Rhou,
Rasd1), apoptosis (5-fold, P < 0.01; for example, Gadd45
g, Sgk1) and the cell cycle (4.7-fold, P < 0.01; for example,
Gadd45 g, Nedd9) .  A n a l y s i s  o f  pa t t e rn  B 2 revealed the
enrichment of genes connected to enzyme inhibitor
activity (8.9-fold, P < 0.05; for example, Cdkn1a, Angptl4),
the stress response (4.2-fold, P  < 0.01; for example,
Cdkn1a, Tsc22d3) and regulation of cell differentiation
(2.5-fold, P < 0.05; for example, Plekhf1, Zbtb16). Over-
representation of transcripts involved in magnesium ion
binding (8.5-fold, P < 0.05; for example, Itgad, Atp10a)
was observed within gene expression pattern B3. A
detailed description of the results of GO classification is
included in Additional file 7.
Comparison with previously reported gene expression 
profiles
To find points of reference for our results, we compared
the lists of genes from the co-expressed gene patterns
with previously described changes in gene expression
profiles. Literature mining was based on the lists of genes
reported as regulated in published manuscripts or found
in publicly available datasets. Overall, we compared our
data with 1,267 gene sets (Additional file 8).
We found high similarity with pattern A to lists of genes
regulated following cocaine (P = 1.33 × 10-36) and meth-
amphetamine (P = 1.04 × 10-13, FDR-corrected) adminis-
tration [40]. Moreover, significant enrichment of genes
regulated by kainic acid (P = 5.88 × 10-13) and domoic
acid (P = 3.52 × 10-12) in the brain and by forskolin (P =
3.87 × 10-12) in vitro was also found in this group [41-44].
All of these in vivo effects were observed at a relatively
early time point (1 to 2 h after injection) and were con-
nected with the induction of a group of immediate early
gene (IEG) transcription factors and neuroplasticity-
related genes like Fos, Arc, Npas4 and Homer1.
Drug-induced transcription pattern B revealed differ-
ent links with the published gene expression profiles than
gene pattern A. The effects of morphine (P = 1.15 × 10-29)
and ethanol (P = 1.87 × 10-11) on the activation of gene
expression pattern B were in agreement with previous
results [45,46]. These genes were induced between 2 and
4 h following drug injection. The regulation of gene
expression pattern B was somewhat similar to the effects
of the glucocorticoid receptor (GR) agonist dexametha-
sone in the hypothalamus (P = 1.57 × 10-8) [47]. More-
over, expression pattern B contained genes reported to be
up-regulated in response to domoic acid (P = 1.41 × 10-18)Piechota et al. Genome Biology 2010, 11:R48
http://genomebiology.com/2010/11/5/R48
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Table 1: Functional classes, results from literature, and transcription factor binding sites associated with drug-regulated 
patterns of gene expression
Gene 
pattern
Gene ontology Literature mining TFBS over-representation
Term Fold (P)a Dataset Pa Binding sitesb Fold (P)c
AP r o t e i n  p h o s p h a t a s e  
activity
32.4 (0.0036) Rodriguez et al. [108], 
cocaine 1 h
1.33E-36 SRF (MA0083) 5.7 (0.095)
Rhythmic process 14.7 (0.0166) Jayanthi et al. [40], 
methampethamine 2 h
1.04E-13 CREB1 
(MA0018)
3.9 (0.0068)
Phosphotransferase 
activity
10.7(<0.0001) Lemberger et al. [41], 
kainic acid 1 h
5.88E-13
Protein dimerization 
activity
3.6 (0.0203) Ryan et al. [42], domoic 
acid 0.5 and 1 h
3.52E-12
Regulation of 
transcription
3 (0.0001) Impey et al. [43], 
forskolin 1 h
3.87E-12
B1 Small GTPase 
mediated signal 
transduction
5.9 (0.0085) Sanchis-Segura et al. 
[44], morphine 4 h
8.96E-29 Foxd3 
(MA0041)
4.4 (0.02)
Apoptosis 5 (0.0018) Treadwell et al. [46], 
ethanol 6 h
1.87E-11 Foxa2 
(MA0047)
4.2 (0.043)
Cell cycle 4.7 (0.0025) Sato et al. [47], 
dexamethasone 2 h
1.57E-08 FOXF2 
(MA0030)
4 (0.025)
Intracellular 
signaling cascade
3.2 (0.0079) Lemberger et al. [41], 
kainic acid 1 h
9.51E-07 Evi1 (MA0029) 3.8 (0.036)
Intracellular 1.5 (0.0017) Ryan et al. [42], domoic 
acid 4 h
8.90E-07
B2 Enzyme inhibitor 
activity
8.9 (0.041) Korostynski et al. [45], 
morphine 4 h
1.15E-29 NR1H2 
(MA0115)
3.5 (0.288)
Apoptosis 5.9 (0.0007) Ryan et al. [42], domoic 
acid 4 h
1.41E-18 Ar (MA0007) 3.3 (0.074)
Response to stress 4.2 (0.01) McClung et al. [27], 
morphine withdrawal
4.23E-17 NR2F1 
(MA0017)
3.3 (0.0428)
Cell differentiation 2.5 (0.026) Treadwell et al. [46], 
ethanol 6 h
3.58E-13
Intracellular 1.4 (0.0074) Chen et al. [109], heart 
failure left ventricular 
assist device (LVAD)
1.47E-07
B3 Regulation of 
developmental 
process
9.1 (0.0364) Korostynski et al. [45], 
morphine 4 h
3.75E-15 Fos (MA0099) 6.7 (0.0103)
Magnesium ion 
binding
8.5 (0.0416) McClung et al. [27], 
morphine withdrawal
3.52E-10 NR3C1 
(MA0113)
5.6 (0.0058)
Anatomical 
structure 
morphogenesis
3.9 (0.0261) Ryan et al. [42], domoic 
acid 4 h
3.22E-08 Ar (MA0007) 4.7 (0.0021)
Calcium ion binding 3.5 (0.1894) Treadwell et al. [46], 
ethanol 6 h
9.56E-06 TEAD1 
(MA0090)
3.9 (0.0302)Piechota et al. Genome Biology 2010, 11:R48
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at a relatively late time point (4 h after injection; Table 1)
[42].
We also found that gene expression pattern A was simi-
lar to the group of dopamine receptor 1 (D1R) antagonist
(SCH23390)-sensitive methamphetamine-responsive
genes (P = 1.05 × 10-6). In contrast, pattern B1 was similar
to the group of SCH23390-resistant methamphetamine-
responsive genes (P  = 4.20 × 10-5) [40]. A detailed
description of the results of literature mining is included
in Additional file 8.
Identification of transcription factor binding sites
T o  d i s c o v e r  m o l e c u l a r  f a c t o r s  t h a t  a r e  i n v o l v e d  i n  t h e
transcriptional control of the discovered gene expression
patterns, we used an in silico method of transcription fac-
tor binding site (TFBS) identification. We analyzed gene
promoters based on the assumption that a subset of the
co-expressed genes may be co-regulated by common
transcription factors. For this purpose, we developed a
new tool for the discovery of over-represented TFBSs: the
cREMaG database (see Materials and methods).
Gene expression pattern A revealed the highest over-
representation of binding sites for serum response factor
(SRF)/serum-responsive elements (5.7-fold higher than
expected by chance, P = 9.5 × 10-3). Significant over-rep-
resentation of TFBSs for transcription factor cyclic AMP-
response element binding protein (CREB)/cyclic AMP
response elements (3.9-fold, P  = 6.8 × 10-3) was also
found. We identified an over-representation of cyclic
AMP response elements (the binding site for the CREB
transcription factor) and serum-responsive elements (the
binding site for the SRF transcription factor) in the core
promoter regions of genes with expression pattern A. The
complementary roles of these transcription factors have
been independently confirmed [41,48].
The analysis of the promoter regions of pattern B1
genes indicated an over-representation of the binding site
for transcription factors of the FOX family, Foxd3/FRE
(4.4-fold, P = 1.96 × 10-2). Forkhead transcription factors
are implicated in the neuronal response to oxidative
stress [49]. Promoter regions of genes from expression
pattern B2 contained relatively more binding sites for ste-
roid hormones NR1H2-RAXR (3.5-fold, P = 2.88 × 10-2)
and Ar/ARE (3.3-fold, P = 7.4 × 10-2) with transcriptional
activity. An enrichment of binding sites for nuclear recep-
tors in promoter regions, including the androgen recep-
tor (ARE/Ar), was found, suggesting that genes from this
subgroup may be regulated by steroid hormones. Over-
representation of binding sites for Fos/AP1 (6.7-fold, P =
1.03 × 10-2) and NR3C1/GRE (5.6-fold, P = 5.8 × 10-3) was
observed within promoter regions of genes from pattern
B3 (Table 1). Components of the transcriptional complex
AP-1 (Fos,  Fosb) exhibited gene expression pattern A.
Therefore, the occurrence of an AP-1 site in the promoter
regions of genes expressed relatively late following drug
administration may indicate target genes for the drug-
activated transcription factors. The second putative
mechanism of B3 gene regulation is related to the effects
of glucocorticoid hormones on the central nervous sys-
tem.
Pharmacological dissection of drug-regulated gene 
patterns
The effects of selected pharmacological tools on drug-
induced gene expression changes were analyzed using
DNA microarrays. This novel approach allowed us to
modulate the drug-induced gene transcription and to dis-
sect the particular genetic networks. Based on the results
of the primary microarray experiment, six potential
m e c h a n i s m s  o f  g e n e  r e gu l a t i o n  w e r e  t e s t e d  ( F i gu r e  4 ) .
However, due to an increase in the number of factors
(various inhibitors and vehicles), it was not possible to
perform all experiments in the time-course. Therefore,
for each analysis, a drug and a time point identified in the
first experiment as producing the maximal transcrip-
tional effect were chosen (Additional file 6). Taking into
account previously suggested anti-addictive properties of
the substances that attenuate gene expression patterns
[50-53], these results are important for further studies of
potential therapeutic drugs.
The selected regulatory processes were tested for their
influence on drug-induced gene expression pattern A.
Pre-treatment with a D1R antagonist (SCH23390)
blocked drug-induced CREB1/SRF-mediated gene tran-
scription in the striatum, with a 126% reduction (26% of
induction below basal level) in the level of cocaine activa-
Transmembrane 
transporter activity
3.4 (0.1973) Hasan et al. [110], 
chronic oxycodone
7.61E-05
The complete results of data-mining are presented in Additional files 7 and 8. aStatistical significance of gene enrichment was computed 
using algorithms implemented in DAVID 2008 database and ErmineJ software. bConserved promoter regions +5,000/-1,000 bp from the 
transcription start site were analyzed (see Materials and methods). cFold change of the detected number of identified transcription factor 
binding sites (TFBSs) compared to the number expected by chance. dStatistical significance of over-representation of TFBS-containing genes 
compared to a number expected by chance was computed using a z-score test.
Table 1: Functional classes, results from literature, and transcription factor binding sites associated with drug-regulated 
patterns of gene expression (Continued)Piechota et al. Genome Biology 2010, 11:R48
http://genomebiology.com/2010/11/5/R48
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tion (P < 0.001) (Figure 4a). This observation suggested
that the regulatory intracellular cascades are activated
mainly in striatal cells containing D1R. At the same time,
SL327, an inhibitor of extracellular signal-regulated
kinase (ERK1/2) activator kinase MEK1/2, inhibited the
cocaine-activated expression of genes from pattern A,
with a 107% reduction (7% of induction below basal level)
in the level of cocaine activation (P < 0.001) (Figure 4b).
This observation clearly indicates the involvement of the
ERK1/2 signaling pathway [50].
Moreover, the administration of the histone deacetylase
inhibitor trichostatin before cocaine administration pro-
voked an intensification of the transcriptional response,
with a 33% increase in the level of cocaine activation (Fig-
ure 4c). This observation suggested that the induction of
genes from the expression pattern A may require
enhanced chromatin unfolding [54].
Opioids increased the abundance of mRNAs from
expression pattern A 4 h after injection. Pretreatment
with the protein synthesis inhibitor cycloheximide (CHX)
Figure 3 Validation of drug-induced regulation of gene expression. (a) Bar graphs summarizing qPCR-based measurement of changes in select-
ed gene expression after the indicated drug injection, presented as fold change over the saline control group with standard error (n = 5 to 6). Signif-
icant differences in the main effects from multivariate ANOVA for drug treatment are indicated by asterisks (***P < 0.001) and from the Bonferroni post-
hoc test (versus appropriate saline control) by dollar signs (P < 0.05). (b) Bar graphs summarizing qPCR-based measurement of selected gene expres-
sion after morphine (MOR) injection in the home cage or during CPP acquisition and expression. Results are presented as fold change over the saline 
control group (SAL) with standard error (n = 6 to 7). Significant differences in transcript abundance between the morphine-treated and control animals 
obtained by a t-test are indicated by dollar signs (P < 0.05).
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Figure 4 Pharmacological dissection of transcriptional networks from the drug-induced gene expression profile. Microarray results are 
shown as heat maps that include drug-responsive genes with genome-wide significance (Figure 2a). Colored rectangles represent transcript abun-
dance and are labeled below the heat map. Each row contains the mean value from three independent array replicates, where samples from two mice 
were pooled and used for each microarray. The intensity of the color is proportional to the standardized values (between -2 and 2) from each microar-
ray, as indicated on the bar below the cluster images. The names of enzyme inhibitors or receptor antagonists (inhibitor/antagonist) are indicated on 
the left. The time scheme of each experiment (a-g) is presented on the right. The arrow indicates (two-tailed t-test, P < 0.05) up- or down-regulation 
of the expression of a particular gene in comparisons between the drug plus vehicle and saline plus vehicle groups (upper row on each heat map) or 
drug plus inhibitor/antagonist and drug plus vehicle groups (bottom row). The overall influence was measured as a percentage of inhibition of the 
drug-induced transcriptional response, with 0% representing no effect and 100% representing complete inhibition. The statistical significance of in-
fluence was measured as a comparison of the mean fold change between the drug plus inhibitor/antagonist and saline plus vehicle versus drug plus 
vehicle and saline plus vehicle groups. The level of significance was measured using a two-tailed t-test: *P < 0.05; **P < 0.01; ***P < 0.001. CRF, corti-
cotrophin-releasing factor; HDAC, histone deacetylase.
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inhibited this induction, with a 66% reduction in the level
of heroin activation (P < 0.05) (Figure 4d), which indi-
cates that this relatively late response depends on protein
translation.
All of the compared drugs induced gene transcription
pattern B1 in the striatum. The relatively early transcrip-
tional response to heroin (CHX blocked 87% of activa-
tion,  P  < 0.001) and ethanol (CHX blocked 72% of
activation, P < 0.05) was blocked by an inhibitor of pro-
tein synthesis (Figure 4d, e). Similar effects of CHX were
observed on the induction of gene expression pattern B2
in response to heroin (CHX blocked 106% of activation,
6% of activation below basal level, P < 0.001) and ethanol
(CHX blocked 104% of activation, P < 0.001) (Figure 4d,
e).
Microarray results indicated the inhibitory effects of
corticotropin-releasing factor (CRF) receptor 1 (CRFR1)
and GR antagonists (antalarmin and RU486, respectively,
blocked 65% of ethanol activation, P  < 0.05) on gene
expression activation of the B3 subcluster (Figure 4f, g).
RU486 also altered the expression of several B1 genes, for
example,  Sgk1  and  Plekhf1  (Figure 4g). Therefore, the
i n fl u e n c e  o f  G R  r e c e p t o r  b l oc k a g e  o n  e t h a n o l - i n d u c ed
expression of B1genes could not be correctly evaluated.
Correlation with behavioral drug effects
To link the gene expression patterns with drug-related
phenotypes, we analyzed the correlations between the
transcriptional and behavioral drug effects in mice.
Mutual interactions between the brain gene expression
and behavioral profiles are complex and multidimen-
sional. Therefore, it is difficult to define them using anal-
yses performed with only the few available data points.
However, even speculative results obtained from this
analysis create the unique possibility of assigning differ-
ent transcriptional alterations induced by various drugs
to drug-related phenotypes. We observed a positive cor-
relation of r = 0.62 (Pearson's method, P < 0.001) between
the level of drug-induced locomotor activation and the
degree of transcriptional response of gene expression pat-
tern A. Additionally, we found a significant correlation
between the acute induction of B1 genes and the reward-
ing effect of the drug (r = 0.7, Pearson's method, P < 0.05;
Figure 1c, d; Additional file 9).
Evaluation of two drug-regulated genes at the mRNA and 
protein levels
We selected two genes from expression pattern B for fur-
ther evaluation. The first gene, Sgk1, encodes the SGK
protein (serum-and glucocorticoid-inducible kinase) and
exhibited the B1  pattern. The second gene, Tsc22d3,
encodes the GILZ protein (glucocorticoid-induced leu-
cine-zipper protein) and exhibited the B2 pattern. We
inspected alterations in mRNA abundance in the stria-
tum during the acquisition and expression of the mor-
phine-induced CPP. Both genes were induced 4 h after
each of three subsequent sessions of morphine-induced
(20 mg/kg i.p.) conditioning (between 1.5-fold and 3-fold
over the control group). However, transcription of Sgk1
and  Tsc22d3  was not activated during the behavioral
expression of morphine-induced CPP (Figure 3b).
Furthermore, in situ hybridization was used to analyze
the brain distribution of drug-induced changes in Sgk1
and Tsc22d3 expression. Both genes showed widespread
induction throughout the brain, including the striatum.
These results are in agreement with the microarray and
qPCR data and confirm the strong striatal activation of
both genes 4 h after morphine injection (20 mg/kg i.p.).
More specifically, activation of Tsc22d3 in the striatum
was limited to the medio-ventral region (nucleus accum-
bens), while Sgk1 was induced ubiquitously in the whole
striatum (Figure 5a).
Western blotting was used to determine whether the
changes in gene expression were translated into altera-
tions in protein levels. The morphine-induced increase in
Sgk1  abundance was associated with a significant
decrease in the level of the protein (0.75-fold). Therefore,
Sgk1 expression changes might be a compensatory effect
to the loss of the protein. Up-regulation of Tsc22d3 was
associated with an increase in the corresponding protein
level (approximately 1.5-fold; Figure 5c). Double-immun-
ofluorescence labeling with neuronal (NeuN) and astro-
glial (S100B) markers was used to identify cells that
expressed SGK (Sgk1) and GILZ (Tsc22d3) proteins. In
the mouse striatum, both genes appeared to be expressed
mainly in neurons (Figure 5b).
Drug-responsive genes are involved in the formation of 
dendritic spines
In order to evaluate the roles of GILZ and SGK1 in neu-
ronal plasticity, we knocked these proteins down in cul-
tured primary neurons and analyzed the morphology of
dendritic spines. To knock down our genes of interest, we
first designed three and four short hairpin RNAs (shR-
NAs) against the Tsc22d3 and Sgk1 sequences, respec-
tively, and cloned them into the pSUPER vector. This
approach permits reliable and medium-term gene knock-
down in neurons [55,56]. Next, we transfected hippocam-
pal and cortical neuronal cultures for 3 days with mixes of
shRNAs targeting each of the genes. The neurons were
grown for 14 days before transfection because, at this
stage, neuronal development is already completed and
morphological changes can be attributed to spine plastic-
ity. Co-transfection of green fluorescent protein (GFP)
was used to identify and visualize the morphology of
transfected cells. We used shRNA mixes to decrease the
potential off-target effects of single hairpins and increasePiechota et al. Genome Biology 2010, 11:R48
http://genomebiology.com/2010/11/5/R48
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the probability of successful knockdown. As shown in
Figure 6, cells transfected with control vector (pSUPER)
displayed characteristics of mature neurons with a mush-
room-type spine morphology. Transfection with the
G I L Z  s h R N A  ( G I L Z s h )  m i x ,  h o w e v e r ,  c a u s e d  p r o -
nounced changes in spine morphology. Rather than
mushroom-shaped spines, GILZsh-transfected neurons
had thin, long, filopodia-like protrusions. On the other
hand, transfection with the SGK shRNA (SGK1sh) mix
did not cause pronounced changes in protrusion shape
but resulted in a decrease in protrusion density compared
to control neurons. Therefore, knockdown of GILZ or
SGK1 in mature neurons resulted in changes in dendritic
spine shape or density, respectively.
Discussion
In this study, we aimed to define the sequence of molecu-
lar changes in the striatum in response to various drugs of
abuse. We estimated that the number of genes induced by
administration of the drugs of abuse was limited to
Figure 5 Brain and cellular distribution of two selected drug-regulated genes. (a) False-colored micrographs representing the relative level of 
the indicated mRNA 4 h after saline (SAL) or 20 mg/kg morphine (MOR) treatment revealed by in situ hybridization. Five coronal sections of mouse 
brain are presented, containing: (I) dorsal striatum and nucleus accumbens, (II) mid striatum, (III and IV) dorsal hippocampus and (V) ventral hippocam-
pus/mesencephalon. (b) Confocal fluorescence micrographs showing coronal sections of striatum after immunohistochemical staining against SGK 
(Sgk1, red in the upper panel), GILZ (Tsc22d3, red in the lower panel), NeuN (neuronal marker, green, left) and S100B (glial marker, green, right). Scale 
bar: 50 μm. (c) Immunoblot of striatal lysates from mice 4 h after injection with morphine (MOR, 20 mg/kg i.p.) or saline (SAL) with antibodies against 
SGK and GILZ. The level of significance was measured using a two-tailed t-test: *P < 0.05. Error bars indicate standard error.
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approximately 100. Other studies reveal various numbers
o f  g e n e s  w i t h  a l t e r e d  e x p r e s s i o n  b y  d r u g s  o f  a b u s e
[26,41,44,46]. However, their estimations are based on
arbitrary significance or fold-change thresholds, whereas
our prediction was based on the number of true positives
through a wide range of false discovery rates. The tran-
scriptome changes produced by drugs of abuse were in
contrast to alterations related to the diurnal cycle. While
drugs of abuse produced few robust changes, the diurnal
cycle alters the levels of several thousand transcripts
(Additional file 1).
W e found that almost all identified genes were regu-
lated in concert with other genes in the form of two drug-
responsive transcriptional modules. No other transcrip-
tional modules were identified, even at lower significance
thresholds. Therefore, we can assume that this study
depicted all of the main patterns of induction in the
mouse striatum after administration of drugs of abuse in
rewarding doses. However, a recent study showed that
after administration of higher, neurotoxic doses of meth-
amphetamine, distinct gene expression patterns appear
[40].
The first identified pattern (pattern A) consisted of
IEGs, which are well described and commonly used as
markers of neuronal activation [57-59]. Particular genes
from this cluster were previously identified in the
response to drugs of abuse, including Fos, Fosb and Egr1
[60,61]. Using bioinformatic analyses, we were able to
postulate a role of the CREB and SRF transcription fac-
tors as main regulators of IEGs, which has been suggested
previously [62,63]. Previous studies indicate that the
cocaine-induced activity of CREB and SRF in the stria-
tum is dependent on the D1R-downstream MEK/ERK
signaling pathway [50,64]. Using pharmacological inter-
vention, we established the role of D1R and the MEK/
ERK signaling pathway for the whole group of IEGs.
However, the role of a group of simultaneously expressed
IEGs in neurons is not known. Some genes from pattern
A (Npas4, Homer1a and Arc) may be involved in protect-
ing against neuronal overexcitability [65,66]. Npas4 regu-
lates inhibitory synapse development in an activity-
dependent manner and diminishes the excitatory synap-
tic input neurons receive [67]. Homer1a appears to par-
ticipate in the attenuation of the gradual inhibition of
glutamate receptor-dependent calcium mobilization, as
well as in mitogen-activated protein kinase activation
[68]. Finally, increased expression of Arc may play a role
in reducing AMPA receptor-mediated synaptic transmis-
sion [69,70]. We clearly demonstrated a lack of an effect
of ethanol on the induction of IEGs in the striatum. It is
worth mentioning that the induction of Fos (a member of
pattern A) by cocaine is inhibited by ethanol [71-73]. We
demonstrated that this lack of induction by ethanol was
true for all IEGs. Therefore, the role of striatal IEGs in the
development of ethanol addiction is rendered question-
able.
The second identified pattern (pattern B) is relatively
unknown. To our knowledge, this is the first comprehen-
sive report describing the time- and drug-dependent
induction of this gene expression pattern, although some
of these genes have been previously reported by us and
others [26,45,46]. This pattern consists of three subse-
quent sub-clusters (B1, B2 and B3). The examined drugs of
abuse, with diverse pharmacological actions and behav-
ioral effects, were all able to induce gene transcription of
the relatively early pattern B1. Expression pattern B1
appeared to depend on several regulatory proteins, for
example, transcription factors of the FOX family. The
data also imply that patterns B2 and B3 appear to be regu-
lated by steroid hormones that respond to morphine, her-
oin and ethanol. This is in agreement with activation of
the hypothalamic-pituitary-adrenal axis (HPA) after
administration of opioids and ethanol [74,75]. Our phar-
macological dissection of drug-regulated gene expression
profiles showed the inhibitory effects of CRFR1 and GR
antagonists on ethanol-activated gene expression of the
B2 and B3 subclusters. Therefore, the present results sug-
gested that ethanol- and/or opioid-induced activation of
these genes depends on HPA and the release of steroid
hormones from the adrenal gland. This CRF- and GR-
dependent signaling system is emerging as a key element
of the neuroadaptive changes that are induced by drugs of
Figure 6 The effects of Tsc22d3 and Sgk1 knockdown on dendritic 
spine morphology in cultured primary neurons. Representative mi-
crographs and three-dimensional Imaris reconstructions of dendritic 
segments of hippocampal and cortical neurons are presented. The 
neurons were transfected with pSUPER (control) or GILZsh mix or 
SGK1sh mix in pSUPER on day in vitro 14 for 3 days. GFP was used to 
highlight transfected cell morphology.
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abuse [76-78]. The identification of novel drug-respon-
sive genes downstream of CRF/GR may help uncover the
molecular mechanisms linking stress and addiction
[79,80]. Pattern B genes modulate various aspects of cell
functioning: hexose transport (Slc2a1), lipid metabolism
(Angptl4, Pparg), regulation of sodium channels and the
actin cytoskeleton (Sgk1) and regulation of the cell cycle
(Cdkn1a), to mention just a few [81-84]. Our results
clearly revealed qualitative and quantitative differences
between the transcriptional networks affected by drugs of
abuse. Therefore, it appears that various molecular mech-
anisms induced by drugs may lead to common addictive
behaviors.
Previous studies show that cocaine administration
leads to the release of glucocorticoids [85]. However, in
our experiments, cocaine did not induce glucocorticoid-
responsive genes (patterns B2 and B3). Expression of these
genes was also affected relatively weakly by methamphet-
amine, compared to the much stronger effects of opioids
a n d  e t h a n o l .  N o t a b l y ,  b o t h  p s y c h o s t i m u l a n t s  w e r e  t h e
only drugs in our study that produced a prominent induc-
tion of IEGs (pattern A) within the first hour after drug
injection. The pattern A genes included components of
the transcription factor AP-1 (Fos, Fosl2, Fosb). Since AP-
1 is a potent repressor of GR activity [86], it seems that
GR-mediated effects of HPA activation on gene tran-
scription in the striatum after psychostimulant adminis-
tration may have been inhibited by previous induction of
the AP-1 complex proteins due to D1R activation. More-
over, the identified clusters A and B contained their self-
repressors. The IEG group contained ICER, an isoform of
Crem, which acts as a powerful repressor of cyclic AMP-
induced transcription [87]. Pattern B, which was partially
controlled by glucocorticoids, includes Fkbp5, a chaper-
one that inhibits GR translocation into the nucleus [88].
HPA activation is one of the most recognized attributes
of stress. Moreover, HPA activation is also a common
effect of various drugs of abuse [74,75,85,89]. Chronic
exposure to stress is associated with increased vulnerabil-
ity to addiction [90,91]. The enhancing effects of stress on
drug self-administration have also been documented in
animal models [92]. Moreover, Mantsch et al. [93] show
that corticosterone itself produces almost the same
effects on drug taking as stress. Therefore, it is possible
that corticosterone released after drug administration
enhances the rewarding properties of the subsequent
drug doses in the same way stress does. The mechanism
of corticosterone contribution to addiction vulnerability
is not well understood. Steroid-mediated enhancement of
mesocorticolimbic dopamine neuron activity has been
suggested to play a role [92].
A correlation analysis between the induction of gene
clusters and the behavioral effects of particular drugs
revealed that the induction of both B1 and B2 gene pat-
terns may be associated with the rewarding effects of
drugs. The present results suggested that two genes, rep-
resentatives of patterns B1 (Sgk1) and B2 (Tsc22d3), might
be associated with neuroplastic changes after administra-
tion of drugs of abuse. Some other authors have
attempted to identify the role of Sgk1 in the central ner-
vous system [94-96]. We demonstrated that knockdown
of Sgk1 expression in neurons caused lower protrusion
density and altered formation of dendritic spines [97].
GILZ (Tsc22d3) has already been considered in the con-
text of its neuronal function [42,45,80]. However, we are
the first to show that knockdown of Tsc22d3 provoked
changes in spine morphology. Rather than mushroom-
shaped spines, GILZsh-transfected neurons had thin,
long, filopodia-like protrusions. These cellular changes
may reflect an altered potential for neuronal plasticity
and could be involved in the positive effect of corticoster-
one on vulnerability to addiction.
Conclusions
We have identified two gene expression patterns that
were induced in the striatum by various drugs of abuse
and demonstrate that these patterns are the only ones
induced by rewarding doses of these drugs. The gene pat-
terns were not equally induced by the various drug
classes. Therefore, clear differences between various
drugs of abuse exist. We then identified upstream factors
that control the discovered patterns. One of the patterns
is at least partially controlled by HPA activation. We pro-
posed a molecular mechanism that is involved in the
HPA-activated enhancement of drugs' rewarding proper-
ties. Finally, we selected two genes and confirmed their
influence on neuronal plasticity. In conclusion, this study
provides valuable comparisons of the actions of various
drugs of abuse on the striatal transcriptome and identifies
potential target genes responsible for drug-induced neu-
roplasticity.
Materials and methods
Animals
Adult male (8 to 10 weeks old) C57BL/6J inbred mice
were housed 6 to 10 per cage, under a 12-h dark/light
cycle, with free access to food and water. Animals weigh-
ing 20 to 30 g were used throughout the experiments. The
animal protocols used in the study were approved by the
local Bioethics Commission at the Institute of Pharma-
cology, Polish Academy of Sciences (Krakow, Poland).
Drug treatment
Mice were sacrificed by decapitation 1, 2, 4 or 8 h after a
single morphine (20 mg/kg), heroin (10 mg/kg), ethanol
(2 g/kg), nicotine (1 mg/kg), methamphetamine (2 mg/
kg) or cocaine (25 mg/kg) i.p. injection, with respective
saline and naïve control groups. The inhibitors and
antagonists used in the secondary microarray experimentPiechota et al. Genome Biology 2010, 11:R48
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were i.p. injected 30 minutes before any of the drugs of
abuse and were dissolved in an appropriate vehicle: 1 mg/
kg SCH23390 (Biotrend, Koln, Germany) in saline; 30
mg/kg SL327 (Biotrend) in dimethyl sulfoxide (DMSO;
Sigma-Aldrich, Steinheim, Germany); 40 mg/kg RU486
(Biotrend) in 3% Tween 20 (Sigma-Aldrich); 75 mg/kg
cycloheximide (Biotrend) in saline; and 20 mg/kg anta-
larmin (Sigma-Aldrich) in 10% Cremophor EL (Sigma-
Aldrich). Trichostatin (Sigma-Aldrich; 1 mg/kg in
DMSO) injections were given 2 h before the cocaine. The
doses of inhibitors/antagonists were based on the litera-
ture, paying particular attention to their ability to block
drug-induced behavior.
Behavioral testing
CPP tests were performed using an unbiased procedure
in a three-arm apparatus. The experiment consisted of
the following phases separated by 24 h: pre-conditioning
test (day 0), conditioning with a drug dose as explained
above (days 1, 3, 5), conditioning with saline (days 2, 4, 6)
and post-conditioning test (day 7). For ethanol and nico-
tine, the procedure was prolonged to five sessions of con-
ditioning. An independent group of animals was tested
for drug-induced motor activation. Locomotor activity
was measured in an activity cage in 15-minute intervals
for 4 h following acute drug treatment.
Tissue collection and RNA preparation
Samples containing the rostral part of the caudate puta-
men and the nucleus accumbens (referred to hereafter as
the striatum) were collected. Tissue samples were placed
in RNAlater reagent (Qiagen Inc., Valencia, CA, USA)
and preserved at -70°C. Samples were thawed at room
temperature and homogenized in 1 ml Trizol reagent
(Invitrogen, Carlsbad, CA, USA). RNA was isolated fol-
lowing the manufacturer's protocol and further purified
using the RNeasy Mini Kit (Qiagen Inc.). The total RNA
concentration was measured using a NanoDrop ND-1000
Spectrometer (NanoDrop Technologies Inc., Montcha-
nin, DE, USA). RNA quality was determined by chip-
based capillary electrophoresis using an RNA 6000 Nano
LabChip Kit and Agilent Bioanalyzer 2100 (Agilent, Palo
Alto, CA, USA), according to the manufacturer's instruc-
tions. RNA from two mice was pooled to create a sample
for each microarray.
Gene expression profiling
A starting amount of 200 ng high-quality total RNA
(equally pooled from two animals) was used to generate
cDNA and cRNA with the Illumina TotalPrep RNA
Amplification Kit (Illumina Inc., San Diego, CA, USA).
The procedure consisted of reverse transcription with an
oligo(dT) primer bearing a T7 promoter using Array-
Script. The obtained cDNA became a template for in
vitro transcription with T7 RNA polymerase and biotin
UTP, which generated multiple copies of biotinylated
cRNA. The purity and concentration of the cRNA were
checked using an ND-1000 Spectrometer. Quality cRNA
was then hybridized with Illumina's direct hybridization
array kit (Illumina). Each cRNA sample (1.5 μg) was
hybridized overnight to the MouseWG-6 BeadChip
arrays (Illumina) in a multiple-step procedure according
to the manufacturer's instructions; the chips were
washed, dried and scanned on the BeadArray Reader
(Illumina). Raw microarray data were generated using
BeadStudio v3.0 (Illumina). Three biological replicates of
the microarrays were prepared per experimental group. A
total of 108 Illumina MouseWG-6 v1.1 and 84 Illumina
MouseWG-6 v2 microarrays (with probes for approxi-
mately 48,000 transcripts) were used in the two experi-
ments. To rule out the effects of injection and
fluctuations related to circadian rhythms, we compared
the drug effects to saline-treated and naïve animals. The
microarray experimental design involved pooling two
animals per array and combining three independent
arrays per group. To provide an appropriate balance in
the whole dataset, groups were equally divided between
the array hybridization batches.
Microarray data analysis
Microarray quality control was performed using BeadAr-
ray R package v1.10.0. The following parameters were
checked on all 192 arrays: number of outliers, number of
beads and percent of detected probes. After background
subtraction, the data were normalized using quantile nor-
malization and then log2-transformed. The obtained sig-
nal was taken as the measure of mRNA abundance
derived from the level of gene expression. The results
were standardized to reduce the effect of hybridization
batches using z-score transformation. Statistical analysis
of the results was performed using two-way ANOVA (for
the factors drug and time) followed by Bonferroni correc-
tion for multiple testing. Alternatively, the FDR (percent
FDR) was estimated using the Benjamini and Hochberg
method [39]. To obtain drug-versus-saline comparisons,
two-way ANOVA was followed by Tukey's post-hoc test.
All statistical analyses were performed in R software ver-
sion 2.8.1 [98]. Gene cross-annotation between the two
versions of each microarray was performed automatically
based on probe sequence, transcript ID and gene identi-
fier, with some manual corrections.
Cluster analysis
Hierarchical clustering was performed using the measure
of Euclidian distance and average distance linkage meth-
ods. The cluster separation was performed according to
an arbitrary threshold (h = 13). Several alternative clus-
tering strategies produced similar hierarchical relation-
ships, as shown in Figure 2a. Cluster visualization was
performed using dChip software [99].Piechota et al. Genome Biology 2010, 11:R48
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Functional annotation, GO enrichment, cell type 
enrichment and literature mining
The functional annotation analysis tool DAVID 2008 was
used to identify over-represented ontologic groups
among the gene expression patterns and to group genes
into functional classifications [100]. The list of transcripts
represented on the Illumina Mouse WG-6 v1.1 microar-
ray was used as a background list. Over-represented GO
terms were defined as having at least three transcripts
and  P  < 0.05 under Fisher's exact test. For cell-type
enrichment of mRNA, a recently published brain tran-
scriptome database was used [101]. The database of 1267
gene lists was used for the literature enrichment analysis.
This included gene lists manually extracted from the pub-
lished data, as well as a collection of gene sets from the
MSigDB database [29]. The statistical significance analy-
sis of transcript enrichment was performed using the
ORA algorithm in ErmineJ software [102]. Annotation
handling was based on Mouse Gene Symbol IDs (MGI),
and all other annotation formats were translated using
BioMart [103]. Input data, annotations and the obtained
results are included in Additional files 2, 7 and 8.
Identification of transcription factor binding sites enriched 
in co-regulated transcripts
The identification of over-represented TFBSs was per-
formed using the cREMaG database [104] with default
parameters. Briefly, a 70% conservation threshold and a
maximum number of 50 conserved TFBSs in non-coding
regions between 5,000 bp upstream and 1,000 bp down-
stream of the transcriptional start site were used. Func-
tional promoter sequences were identified by alignments
between 5' upstream sequences of mouse and human
orthologous genes. The identification of TFBSs was per-
formed using the Perl TFBS module and matrices from
the JASPAR database [105]. MGI Gene Symbol lists were
submitted, and default parameters were used.
Validation of microarray data by qPCR
We performed qPCR measurements for a set of genes
representative of the identified gene clusters. Reverse
transcription was performed with Omniscript Reverse
Transcriptase enzyme (Qiagen) at 37°C for 60 minutes.
The reaction was carried out in the presence of the RNase
inhibitor rRNAsin (Promega, Madison, WI, USA), and an
oligo(dT16) primer (Qiagen) was used to selectively
amplify mRNA. qPCR reactions were performed using
Assay-On-Demand TaqMan probes (Additional file 3)
according to the manufacturer's protocol (Applied Bio-
systems, Foster City, CA, USA) and were run on an iCy-
cler (Bio-Rad, Foster City, CA, USA). For each reaction,
approximately 50 ng of cDNA synthesized from a total
RNA template (isolated from an individual animal) was
used (n = 4 to 10). To minimize the contribution of con-
taminating genomic DNA, primers were designed to span
exon junctions. Additionally, control reactions without
reverse transcription enzyme for each assay were per-
formed. The amplification efficiency for each assay was
determined by running a standard dilution curve. The
expression of the Hprt1 (hypoxanthine guanine phospho-
ribosyl transferase 1) transcript, which had a stable
mRNA level, was quantified to control for variations in
cDNA levels. The cycle threshold values were calculated
automatically by iCycler IQ 3.0a software with default
parameters. The abundance of RNA was calculated as 2-
(threshold cycle).
Measurement of the effects of pharmacological dissection
Further microarray experiments were performed to ana-
lyze the effects of selected pharmacological tools on
drug-induced gene expression changes. Mean fold
changes of drug-induced transcriptional activation for
each gene expression pattern with and without the
administration of a particular inhibitor or antagonist
were compared. The influence was measured as a per-
centage of inhibition of the drug-induced transcriptional
response, with 0% representing no effect and 100% repre-
senting complete inhibition. The statistical significance of
influence was measured as a comparison of the mean fold
change between the drug plus inhibitor/antagonist and
saline plus vehicle versus drug plus vehicle and saline plus
vehicle groups. All necessary controls, including different
vehicles and time points, were included.
Association of gene expression patterns with phenotype
The correlation between the effects of the drugs and
behavioral effects in animals was measured using Pear-
son's method. The mean expression change of each gene
was summarized for all time points together for correla-
tion with CPP and for single time points for correlation
with locomotor activation.
Western blotting
Protein was extracted from the samples using RIPA buf-
fer. The protein concentration of each sample was deter-
mined using the BCA Protein Assay Kit (Sigma-Aldrich).
Aliquots of crude extracts (containing 5 to 20 μg of pro-
tein) were then subjected to electrophoresis on a 12%
SDS-polyacrylamide gel, and proteins were electroblot-
ted onto microporous polyvinylidene difluoride (PVDF)
membranes (Roche, Germany). The membranes were
blocked for 1 h, washed and incubated overnight with
primary antibodies at 4°C. After washing, immunocom-
plexes were detected using a Chemiluminescence West-
ern Blotting Kit (Mouse/Rabbit, Roche), visualized with a
Fujifilm LAS-1000 fluoroimager system and quantified
using Image Gauge software (Fujifilm, Tokyo, Japan). For
immunoblotting, a rabbit polyclonal antibody raisedPiechota et al. Genome Biology 2010, 11:R48
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against: a synthesized non-phosphopeptide derived from
human SGK1 around the phosphorylation site of serine
78 (P-P-SP-P-S; Abcam, Cambridge, MA, USA); or a syn-
thetic peptide conjugated to keyhole limpet hemocyanin
derived from residue 100 to the carboxyl terminus of
Mouse GilZ/TilZ (Abcam) was used. To control for trans-
fer quality, each PVDF blot was stained with Ponceau S.
In situ hybridization
The frozen brains were cut into 12-μm-thick coronal sec-
tions on a cryostat microtome CM 3050S (Leica Micro-
systems, Germany), and the sections were thaw-mounted
on gelatin-chrome alum-coated slides and processed for
in situ hybridization. The hybridization procedure was
performed as previously described [106]. Briefly, the sec-
tions were fixed with 4% paraformaldehyde, washed in
PBS and acetylated by incubation with 0.25% acetic anhy-
drite (in 0.1 M triethanolamine and 0.9% sodium chlo-
ride). The sections were then dehydrated using increasing
concentrations of ethanol (70 to 100%), treated with chlo-
roform for 5 minutes and rehydrated with decreasing
concentrations of ethanol. The sections were hybridized
for 15 h at 37°C with oligonucleotide probes complemen-
tary to nucleotides 493-536 of the mouse Tsc22d3 cDNA
(5'-CAGTTGCTCGGGGCTTGCCAGCGTCTTCAG-
GAGGGTGTTCTCGC-3'; NM 010286.3) and nucle-
otides 1682-1725 of the mouse Sgk1  cDNA (5'-
TTGATCACAGCTCAGACAGACTGCGGGGATTC-
CTCTTAGACCTG-3'; NM 011361.1). The probes were
labeled with 35S-dATP by the 3'-tailing reaction using ter-
minal transferase (MBI Fermentas, Vilnius, Lithuania).
After hybridization, the slices were washed three times
for 20 minutes with 1×SSC/50% formamide at 40°C and
twice for 50 minutes with 1×SSC at room temperature.
Then, the slices were dried and exposed to phosphorim-
ager plates (Fujifilm) for 5 days. The hybridization signal
was digitized using a Fujifilm BAS-5000 phosphorimager
and Image Reader software.
Immunohistochemistry
The animals were deeply anesthetized (pentobarbital, 60
mg/kg i.p.) and perfused transcardially with saline fol-
lowed by 4% paraformaldehyde in 0.1 M phosphate buf-
fer, pH 7.4. Brains were removed, postfixed for 4 h,
transferred to PBS and stored at 4°C. Free-floating sec-
tions were cut 40-μm thick using a Leica vibratome. For
double-immunofluorescence labeling, sections were
blocked for 1 h in 5% donkey serum, pH 7.4 (Vector Labs,
Burlingame, CA, USA) and then incubated overnight at
4°C in a mixture of primary antibodies. Respective pairs
of antibodies included rabbit polyclonal anti-GILZ
(1:100; Abcam) or rabbit polyclonal anti-SGK1 (1:400;
Abcam) with mouse monoclonal anti-s100-beta (1:1,500;
Sigma-Aldrich) or mouse monoclonal anti-NeuN (1:250;
Chemicon, Rosemont, IL, USA). After three washes in
PBS, double immunofluorescence was revealed by incu-
bating the sections for 2 h at room temperature in a mix-
ture of secondary antibodies: Alexa Fluor 488-conjugated
donkey anti-mouse IgG and Alexa Fluor 555-conjugated
donkey anti-rabbit IgG (both at 1:750; Molecular Probes
Inc., Eugene, OR, USA). The sections were washed three
times with PBS, mounted on slides in Vectashield (Vector
Labs) and coverslipped. The negative controls were pre-
pared by omitting the primary antibody. The sections
were examined using a 63× objective on a confocal
microscope (DMRXA2 TCS SP2, Leica Microsystems).
The background noise of each confocal image was
reduced by averaging four scans per line and four frames
per image. To visualize image details, plates were gener-
ated adjusting the contrast and brightness of digital
images (ImageJ, NIMH).
Primary neuron cultures and transfection
Primary hippocampal and cortical cultures were pre-
pared from embryonic day 16 mouse brains, according to
the Banker and Goslin procedure. Cells were plated on
coverslips coated with poly-L-lysine (30 μg/ml; Sigma)
and laminin (2 μg/ml; Roche) at a density of 500 (hip-
pocampal) or 1,250 (cortical neurons) cells/mm2. Neu-
ronal cultures were grown in Neurobasal medium
(Invitrogen) supplemented with B27 (Invitrogen), 0.5
mM glutamine, 12.5 μM glutamate and penicillin/strep-
tomycin mix (Sigma). On the 14th day in vitro (DIV),
neurons were transfected with Lipofectamine 2000
(Invitrogen) for 3 days, as previously described [55].
Briefly, for cells growing in a single well of a 24-well dish,
0.9 μg of DNA was mixed with 1.67 μl of Lipofectamine
2000 in 100 μl of Neurobasal medium and incubated for
30 minutes. During the incubation time, fresh culture
media were prepared, mixed half and half with old media
and split into two equal aliquots. The first aliquot was
added to the cells, and the second was saved during the
transfection period. Next, complexes of DNA with Lipo-
fectamine 2000 were added to the cells and incubated for
4 h at 37°C, 5% CO2. Finally, cells were washed twice with
Neurobasal medium and incubated in the saved culture
media. The pSUPER vector [107] and β-actin-GFP [56]
mammalian expression plasmids have been described.
GILZ shRNAs were designed against mouse GILZ
(Tsc22d3) mRNA (EntrezGene ID: 14605) targeting
nucleotides 383-401, 385-407 and 437-459, respectively.
SGK1 shRNAs targeted nucleotides 265-283, 719-737,
975-993 and 1008-1026 of Sgk1 (EntrezGene ID: 20393),
respectively. All shRNAs were cloned into pSUPER. In
RNA inyerference experiments, the mix of shRNAs
encoding plasmids and β-actin-GFP were cotransfected
at a 3:1 ratio.Piechota et al. Genome Biology 2010, 11:R48
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Immunocytochemistry of in vitro cultured neurons
For immunofluorescent staining of transfected GFP, neu-
rons were fixed with 4% paraformaldehyde containing 4%
sucrose in PBS for 10 minutes at room temperature. After
fixation, cells were washed three times with PBS for 5
minutes at room temperature and incubated with pri-
mary antibody in GDB buffer (0.2% gelatin, 0.8 M NaCl,
0.5% Triton X-100 and 30 mM phosphate buffer, pH 7.4)
overnight at 4°C. Cells were then washed three times with
PBS for 10 minutes at room temperature. Secondary anti-
Figure 7 A proposed scheme of the core regulatory network of drug-induced molecular mechanisms and gene expression alterations in 
the striatum. Small nodes represent transcripts belonging to the identified gene expression patterns. The color of each node reflects its gene pattern 
membership: blue, A; yellow, B1; orange, B2; and red, B3. Thin blue edges between the nodes indicate a correlation between the expression profiles of 
two genes. Functional connections were implemented based on our results from literature mining, pharmacological experiments and in silico predic-
tions of TFBSs. Large hexagonal nodes represent elements of drug-activated signaling pathways. Solid and dashed edges between the nodes indicate 
direct or indirect interactions, respectively, as suggested by the literature. A red node color and thin red edge indicate a pharmacologically verified 
connection (Figure 4). Green triangle nodes represent gene transcription regulatory elements. Thin green edges indicate positive detection of TFBSs 
in a promoter region of a particular gene. Transparent arrows suggest the influence of gene expression changes on addiction-related traits based on 
the correlations between the transcriptional and phenotypic response (Figure 1c, d; Additional file 9).
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bodies were applied in GDB for 1 h at room temperature
and washed out by three 10-minutes PBS washes. The
secondary antibodies were rabbit anti-GFP (Medical and
Biological Laboratories Co. Ltd., Nagoya, Japan) and anti-
rabbit Alexa Fluor 488-conjugated secondary antibody
(Invitrogen). Confocal images of cells were obtained with
sequential acquisition settings at the maximal 1,024 ×
1,024 pixel resolution of the Zeiss LSM 5 Exciter micro-
scope (Carl Zeiss, Germany). Each image was a z-series of
images, and each was averaged two times. The obtained
stacks were directly analyzed using Imaris v6.3.1 (Bit-
plane AG, Zurich, Switzerland). The changes in spine
length, diameter and volume were quantified based on
the three-dimensional reconstructions computed by
Imaris.
Regulatory network modeling
Putative drug-activated signaling pathways and interac-
tions between the transcription factors and drug-respon-
sive genes were modeled. Data were integrated based on
our results from gene expression profiling, pharmacologi-
cal experiments and in silico predictions of TFBSs. Only
strong correlations (r > 0.6) between the expression pro-
files of two genes and pharmacologically verified connec-
tions (P < 0.1) were analyzed. The main construction of
signaling pathways was based on the literature. To gener-
ate the molecular network shown in Figure 7, we used
Cytoscape software.
Accession codes
Microarray data were submitted to the NCBI Gene
Expression Omnibus (GEO) under accession number
[GEO:GSE15774].
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Additional file 1 A figure presenting ANOVA results of gene expression 
profiling of drug effects in mouse striatum. The upper panel shows the rela-
tionship between the number of true positive results and the proportion of 
false positives for (a) time and (b) drug factors and (c) their interaction in 
ANOVA. The lower panel presents the relationship between the obtained P-
values (y-axis) for both the factors and their interaction and the theoreti-
cally expected P-values (x-axis).
Additional file 2 A table listing the results of two-way ANOVA (followed 
by correction for multiple comparisons or Tukey's post-hoc test). The lists 
include: those genes altered by drug treatment, by time and with interac-
tion between the factors; those genes regulated by each particular drug (P 
< 0.05, versus saline); and the expression levels of genes from patterns A 
and B. Each of these is available as a separate spreadsheet. P-values 
obtained from two-way ANOVA were further corrected using Bonferroni or 
Benjamini and Hochberg (percent FDR) corrections.
Additional file 3 A data file providing the results from the qPCR validation 
of the microarray data. Results for selected genes are presented as the 
mean (± standard error) compared with the saline control group (n = 3 to 
10). A list of TaqMan assays used in the qPCR experiments with IDs and 
exon boundaries is included as a separate sheet.
Additional file 4 A figure showing hierarchical clustering of drug-induced 
gene expression alterations in mouse striatum. Microarray results are 
shown as a heat map and include genes with a significance obtained from 
two-way analysis of variance of the drug factor at (a) 5% and (b) 29% of 
FDR. Colored rectangles represent the transcript abundance (Additional file 
5) of the gene and are labeled on the right. The intensity of the color is pro-
portional to the standardized values (between -2 and 2) from each microar-
ray, as indicated on the bar below the heat map image.
Additional file 5 A figure showing chromosome localizations of drug-
responsive genes.
Additional file 6 A figure showing comparison of drug-induced effects in 
mouse striatum. (a-g) Average activity of time-dependent, drug-induced 
gene expression patterns. The results are presented as mean changes in 
gene expression (measured using z-values, in the extended A, B1, B2 and B3 
groups of genes). The values are relative to the level of transcript abun-
dance in naïve animals (at each of the time points 1, 2, 4 and 8 h). The thick-
ness of the line is proportional to the number of genes in each cluster. (h,i) 
Matrices of correlation between all compared drug-induced gene expres-
sion profiles. The results were obtained using (h) DNA microarrays and (i) 
qPCR. The qPCR analysis was used to validate microarray results (Additional 
file 3).
Additional file 7 A table listing the complete results of the GO analysis 
presented in the manuscript. The analyses were performed on lists of genes 
that correspond to patterns A, B1, B2 and B3. The genes are listed in Addi-
tional file 2. Selected results are presented in Table 1.
Additional file 8 A table listing the complete results of the literature min-
ing presented in the manuscript. The analyses were performed on lists of 
genes that correspond to patterns A, B1, B2 and B3. The genes are listed in 
Additional file 2. Selected results are presented in Table 1.
Additional file 9 A table providing the results of correlation analysis 
between the transcriptional response to drugs of abuse and behavioral 
traits related to drug abuse (see Materials and methods). Behavioral data 
and the matrix of correlations are available as separate sheets. Gene expres-
sion data from each pattern were normalized using z-score transformation 
and summarized as a function of time. Associations were computed using 
Pearson's correlation.Piechota et al. Genome Biology 2010, 11:R48
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